Tornier Perform™ Reversed Monopost Study
Condition(s) studied
Investigational drug(s) / intervention(s)
Tornier Perform™ Reversed MonoPost: The Commercially available Tornier Perform™ Reversed MonoPost Glenoid is intended to replace the glenoid part of the scapulohumeral joint as part of a reverse shoulder prosthesis.
Study summary
This study is a Multi-center, Prospective Follow-up, Non-significant risk, Post-Market Clinical Follow-Up (PMCF) study to Evaluate the Safety and Effectiveness of the Tornier Perform™ Reversed MonoPost System.
Eligibility
Primary outcome measure(s)
- Performance: American Shoulder and Elbow Surgeons (ASES) score- change in functional ability of the treated shoulder — from baseline to 2 years
The average change in functional ability as measured by the American Shoulder and Elbow Surgeons (ASES) score. ASES is an absolute score ranging from 0 to 100 where a higher score indicates better shoulder function.
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| Eisenhower Health | Rancho Mirage | California | Recruiting |
| Ohio State University | Columbus | Ohio | Recruiting |
More Stryker Trauma and Extremities trials in the USA
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07764614 on ClinicalTrials.gov ↗ ← All trials in the USA